Do CHA2DS2VASc and HAS-BLED scores influence 'real-world' anticoagulation management in atrial fibrillation? 1556 patient registry from the reference cardiology centre

Introduction Although recommendations for the antithrombotic management of atrial fibrillation (AF) are based on strong evidence, the European guidelines are not fully implemented into practice. Objectives The objective of this study is to analyse antithrombotic treatment in AF in Poland after the p...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoepidemiology and drug safety 2015-12, Vol.24 (12), p.1297-1303
Main Authors: Lopatowska, Paulina, Tomaszuk-Kazberuk, Anna, Mlodawska, Elzbieta, Bachorzewska-Gajewska, Hanna, Malyszko, Jolanta, Dobrzycki, Slawomir, Musial, Wlodzimierz J.
Format: Article
Language:English
Subjects:
Anticoagulants
anticoagulation treatment
atrial fibrillation
Cardiac arrhythmia
CHA2DS2VASc score
Coagulation
HAS-BLED score
Heart attacks
pharmacoepidemiology
Pharmacology
Stroke
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Although recommendations for the antithrombotic management of atrial fibrillation (AF) are based on strong evidence, the European guidelines are not fully implemented into practice. Objectives The objective of this study is to analyse antithrombotic treatment in AF in Poland after the publication of the European Society of Cardiology Guidelines in 2012. Patients and Methods We retrospectively studied 1556 patients with AF from the Reference Cardiology University Centre in Poland in 2012–2014. Results CHA2DS2VASc and HAS‐BLED scores were 3.5 ± 1.7 and 2.4 ± 1.1. Anti‐vitamin K agent were prescribed in 59%, with non‐vitamin K antagonist oral anticoagulants in 12%, acetylsalicylic acid (ASA) alone in 18%. Older patients (p 
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.3878